Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 03 Mar 2017 Results published in the European Journal of Cancer
- 11 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2014 Planned End Date changed from 1 Oct 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.